This study is for people with a type of lung cancer called Non-Small Cell Lung Cancer (NSCLC). The study is in Phase I, which means it’s the first step in testing if a new drug, called MYTX-011, is safe and works well. MYTX-011 is a special kind of drug called an antibody-drug conjugate (ADC). It combines an antibody that targets cancer cells with a strong medicine to kill them.

Part 1 of the study checks how safe MYTX-011 is and the best dose to use. Part 2 involves patients with certain gene changes in their cancer. The study is open to those whose cancer has spread and who have tried other treatments already.

• The study is done at multiple centers, which means you might need to travel to get the treatment.
• You need to agree to use birth control during the study and for 6 months after.
• You must have at least one tumor that can be measured and be able to understand and sign a consent form.

Before joining, make sure to discuss with your doctor if this study is a good choice for you.